# A Survival Observational Study in Patients With Advanced IIIB-IV Squamous Cell Lung Cancer Receiving PD-1 Combination With Chemotherapy

> **NCT04306042** · — · UNKNOWN · sponsor: **Guangdong Association of Clinical Trials** · enrollment: 1000 (estimated)

## Conditions studied

- Lung Squamous Cell Carcinoma Stage IV

## Interventions

- **DRUG:** Nivolumab or Pembrolizumab

## Key facts

- **NCT ID:** NCT04306042
- **Lead sponsor:** Guangdong Association of Clinical Trials
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03
- **Primary completion:** 2020-12
- **Final completion:** 2022-12
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2020-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04306042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04306042, "A Survival Observational Study in Patients With Advanced IIIB-IV Squamous Cell Lung Cancer Receiving PD-1 Combination With Chemotherapy". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT04306042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*